Holmusk is a digital solutions company with best-in-class real-world evidence and expertise in behavioral health. They have built the field's largest, most robust clinical database for real-world data and a uniquely powerful evidence engine to revolutionize the behavioral health landscape.

Nawal Roy

Holmusk

Tan Tock Seng Hospital provides healthcare services in Singapore, self-described as serving generations of families for 180 years.

Tan Tock Seng Hospital

Holmusk is a data analytics and health technology company on a mission to harness real-world evidence to transform both research and care for behavioral health. 

Combining a leading behavioral health database with AI-powered analytics and digital solutions designed to address the most pressing challenges in behavioral health, Holmusk is advancing the frontier of evidence generation and fueling innovation. Holmusk’s core offerings include HolCare EHR+, an electronic health records platform with built-in measurement-based care, and NeuroBlu Research, a powerful data analytics solution that enables users to build patient cohorts, explore datasets, and discover new insights. 

Founded in 2015, Holmusk is a global company headquartered in Singapore and New York. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum.

Veradigm

Capikris Foundation

Heritas Capital

Health Catalyst Capital

Optum Ventures

Northwell Ventures

Novartis

Unstructured EHR data in clinical notes is a rich source of clinical information and can be used alongside structured data to offer deeper patient characterization.

Holmusk has developed novel natural language processing (NLP) models specific to behavioral health to extract essential information from unstructured notes. These NLP models are applied to unstructured data, and the resulting insights are made available in NeuroBlu, a powerful analytics tool built to explore the world's richest real-world database for behavioral health.

Read the use case to learn more about how our newest NeuroBlu NLP model substantially increases cohort sizes when applied to unstructured notes for patients diagnosed with a psychotic disorder: https://hubs.li/Q02lTffV0

#RWD #realworlddata #NLP

The landscape of mental health research is evolving, and tools like Natural Language Processing (NLP) hold immense potential to bridge the gap between clinical trials and real-world evidence.

Our latest blog explores how we developed NeuroBlu NLP - novel NLP models designed to extract disease-specific features from unstructured clinical notes. These NLP-derived clinical features are then integrated into our structured data and made available in NeuroBlu, Holmusk’s powerful real-world data analytics software for behavioral health. 

Read the blog to learn more about the complexities of model development and how granular symptomatology data can be captured through the application of novel, fit-for-purpose NLP models: https://hubs.li/Q02lGn_t0

#RWD #realworlddata #NLP


Announcing NeuroBlu v3.8, the first release of 2024! 

This version of NeuroBlu integrates a suite of comprehensive data features and our new NeuroBlu NLP psychotic disorders model for in-depth research across our extensive patient database. NeuroBlu v3.8 is at the forefront of mental health data analysis with enhanced processing speeds and a strategic dataset management update.

Interested in learning more about the largest NLP-enriched, real-world data platform designed for behavioral and mental health? 

Read the release announcement here: https://hubs.li/Q02l72N70

#RWD #realworlddata #NLP

Metric
Company Name	Holmusk	Tan Tock Seng Hospital
Symbol
MSH ID	COM:HOLMUSK	SG:COM:TTSH
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare & Health Services	Hospital and Healthcare Services
Country	US	SG
Stage
Employee Count	107
Website	holmusk.com	ttsh.com.sg
LinkedIn	holmusk
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		174.91K
Web Traffic Growth		0.16
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:HOLMUSK

Holmusk

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue